Padcev is a cancer medicine for treating adults with urothelial cancer (a cancer of the bladder and urinary tract). Padcev is used on its own in patients whose cancer is advanced or metastatic (has spread to other parts of the body) and who have already had platinum-based chemotherapy and an immunotherapy targeting PD-1 or PD-L1. Padcev can also be used in combination with pembrolizumab (another cancer medicine) when the cancer is metastatic or cannot be removed by surgery, and patients have not been treated yet. It contains the active substance enfortumab vedotin.
Therapeutic Indication
### Therapeutic indication Padcev, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. Padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
Therapeutic Area (MeSH)
ATC Code
L01FX13
ATC Item
enfortumab vedotin
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Enfortumab vedotin | N/A | 恩福单抗维多汀 |
EMA Name
Padcev
Medicine Name
Padcev
Aliases
N/A
